<DOC>
	<DOCNO>NCT01970618</DOCNO>
	<brief_summary>RV1162 new medicine develop possible treatment smoking relate lung disease ( also know chronic obstructive pulmonary disease - COPD ) . The main purpose study investigate safety , tolerability pharmacokinetics single repeat dos RV1162 .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics ( PK ) RV1162 Healthy Subjects COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Inclusion Criteria ( subject ) : Sign inform consent document indicate understand purpose procedure require study willing participate study . If woman childbearing potential , must document menstrual period prior first dose willing able use 2 form contraception screen 4 month final dose RV1162 . Must woman child bear potential subject Part C , OR If woman nonchildbearing potential must amenorrhoeic least 1 year appropriate clinical profile , OR If man , must willing able use one contraception method list protocol agree donate sperm , first dose 4 month final dose RV1162 . Have 12lead ECG consistent normal cardiac function Capable comply study restriction procedure include ability use study inhaler correctly . Parts A &amp; B ( healthy volunteer ) Aged 18 50 year age inclusive , time signing informed consent Healthy determine physician , base full medical evaluation include medical history , physical examination laboratory test . Vital sign assessment within normal range Body mass index 19 30 kg/m2 body weight less 50 kg . Spirometry reading ( FEV1 FVC ) ≥80 % predict value FEV1/FVC ratio &gt; 0.7 screening Are take prescription medication ( exception contraceptive hormone replacement therapy ) 14 day prior screen agree use prescription medication throughout duration study . Not take counter medication 14 day prior screen final followup visit Part C ( COPD patient ) Aged 40 75 year age inclusive , time signing inform consent Have diagnosis COPD symptom compatible COPD least 1 year COPD severity classification GOLD Grade II/III Current previous smoker smoke history ≥ 10 pack year Not clinical abnormality laboratory parameter outside reference range Able produce viable induced sputum sample screen visit . Exclusion Criteria ( subject ) : Upper low respiratory tract infection within 4 week screen Clinically significant abnormal value haematology , clinical chemistry urinalysis screen History , reason believe subject history drug alcohol abuse within past 5 year Positive test alcohol drug abuse screen prior dose History clinically significant allergy would contraindicate participation Known allergy study drug excipients formulation Donated blood blood product substantial loss blood ( 500 mL ) within 3 month study drug intention donate blood blood product study . Received experimental drug use experimental medical device within 3 month within period le 5 time drug 's halflife , whichever longer , first dose study drug schedule . If woman , positive pregnancy test screen admission , pregnant , breastfeed plan become pregnant study , woman child bear potential ( subject Part C ) . Positive test human immunodeficiency virus ( HIV ) 1 2 antibody , hepatitis B virus ( HBV ) infection , hepatitis C antibody . Preplanned surgery procedure would interfere conduct study . Employee Investigator study centre , direct involvement propose study study direction Investigator study centre , well family member employee Investigator . Current chronic history liver disease , know hepatic biliary abnormality History regular alcohol consumption within 6 month study average weekly intake &gt; 21 unit male , &gt; 14 unit females The subject unable unwilling comply fully study protocol Subject mentally legally incapacitate Unable unwilling undergo multiple venepuncture procedure subject poor access vein suitable cannulation Any reason Investigator considers make subject unsuitable participate Parts A &amp; B ( healthy volunteer ) History smoking use nicotinecontaining substance within previous 6 month positive carbon monoxide test screen admission Part C ( COPD patient ) A history lifethreatening COPD include Intensive Care Unit admission and/or require intubation A history &gt; 1 hospitalisation COPD previous 2 year prior screen Evidence cor pulmonale clinically significant pulmonary hypertension . Requires routine treatment COPD use one restricted therapy list protocol within 6 week screen A current diagnosis asthma , active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis , interstitial lung disease active pulmonary diseases A history chronic uncontrolled disease Investigator believe clinically significant . A history sleep apnoea . Previous lung resection lung reduction surgery . Active participation pulmonary rehabilitation program Alanine transaminase ( ALT ) &gt; 1.5 x upper limit normal ( ULN ) screen visit . Major surgery , ( require general anesthesia ) within 6 week screen visit , fully recover surgery , plan surgery end study A disclosed history , one know Investigator , significant noncompliance previous investigational study prescribe medication A history unstable , uncontrolled hypertension , diagnose hypertension last 3 month Any reason Investigator considers make subject unsuitable participate Vital sign assessment outside range : blood pressure 100 160 mmHg systolic , inclusive , 55 100 mmHg diastolic ; heart rate 50 100 bpm . Requires oxygen , even occasional basis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>